DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals

Information source: The University of Texas Health Science Center, Houston
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine-Related Disorders

Intervention: Dextro amphetamine sulfate and Modafinil (Drug); modafinil (Drug); Modafinil 400 mg (Drug); Placebo (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: The University of Texas Health Science Center, Houston

Official(s) and/or principal investigator(s):
Joy M. Schmitz, PhD, Principal Investigator, Affiliation: University of Texas

Summary

Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to examine the effects of d-amphetamine and modafinil, when given alone and in combination, in treating cocaine dependent individuals.

Clinical Details

Official title: Pharmacotherapy Dosing Regimen (Cocaine Dependence Population)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Substance use

Secondary outcome:

Medication compliance

medication side effects

Detailed description: Cocaine is a strong central nervous system stimulant that is widely abused throughout the United Sates. Due to its widespread use, it is important to develop an effective treatment for cocaine dependence. Modafinil is a glutamate-enhancing agent. D-amphetamine is a central nervous system stimulant that is approved to treat individuals with narcolepsy and attention deficit disorder. Both modafinil and d-amphetamine may be effective treatments for cocaine dependence. The purpose of this study is to examine the effectiveness of modafinil and d-amphetamine, alone and in combination, in treating cocaine dependent individuals. This study will last 16 weeks. Participants will be randomly assigned to one of four groups: 1) 200 mg dose of modafinil; 2) 400 mg dose of modafinil; 3) 30 mg dose of d-amphetamine combined with 200 mg dose of modafinil; and 4) placebo. All participants will receive 200 mg of modafinil over 4 days. Participants assigned to the 400 mg modafinil treatment group will then receive double the initial dose of modafinil for the duration of the study. Participants in the combined group (modafinil and d-amphetamine) will receive 15 and then 30 mg of d-amphetamine over 4 days.

Eligibility

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Meets SCID criteria for cocaine abuse or dependence

- In general good health. Individuals who are HIV-positive will not be excluded if in

good general health, unless medication interactions exist. Exclusion Criteria:

- Meets diagnostic criteria for psychiatric disorders, including other forms of drug

dependence, other than nicotine

- Current cardiovascular disease, as determined by an electrocardiogram

- On probation or parole if the circumstances do not allow study completion or if

ethical constraints of supervision do not allow confidentiality

- Previously received treatment with d-amphetamine, modafinil, or aripiprazole

- Currently receiving prescribed medication

Locations and Contacts

University of Texas Health Science Center, Houston, Texas 77030, United States
Additional Information

Starting date: March 2006
Last updated: March 2, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017